NineSigma, on behalf of Daiichi Sankyo Co., Ltd., seeks novel drug targets or seeds, which are related to the cancer-neuron axis, an interaction between the nervous system and tumour.
Image credit: GerryShaw/Wikipedia/CC BY-SA 3.0
Recent studies suggest that the nervous system including nerve cells and neural factors exaggerates cancer cell growth in the tumour microenvironment (Trends in Cancer, 2020, Vol 6, 1059-1067). Accordingly, the development of novel anti-cancer drugs targeting the nervous system as well as cancer cells or immune cells that interact with the nervous system has gained attention (Nature Biotechnology, 2020, Vol 38, 115-117).
Oncology is one of the focused research areas of the client. They are looking for innovative collaboration in order to develop cancer drugs targeting the cancer-neuron axis that revolutionize cancer therapy.
Submissions to this Challenge must be received by Aug 3, 2021.
Source: NineSights